FAE1 Antibody

FAT1 Antibody (Atypical Cadherin FAT1)

• Target: FAT1 (FAT atypical cadherin 1), a transmembrane protein involved in cell adhesion and cancer progression.

• Key Antibody: mAb198.3, a monoclonal antibody targeting FAT1 in colorectal cancer (CRC).

  • Specificity: Recognizes FAT1 extracellular domains with high affinity, showing cross-reactivity across species (human, bovine) .

  • Clinical Relevance:

    Parameter	Findings
    Expression in CRC	93% of CRC samples showed FAT1 positivity; 47% with moderate/strong staining .
    Functional Role	Inhibits cancer invasiveness in vitro; reduces tumor growth in xenografts .
    Therapeutic Potential	Effective against KRAS/BRAF-mutant CRC resistant to EGFR-targeted therapies .

FADS1 Antibody (Fatty Acid Desaturase 1)

• Target: FADS1, a front-end fatty acyl-CoA desaturase involved in lipid metabolism.

• Key Antibodies:

  • Cell Signaling Technology #10076: Rabbit monoclonal antibody detecting endogenous FADS1 (43 kDa) in human, mouse, and rat samples .

  • Abcam ab126706: Rabbit monoclonal antibody validated for IHC, WB, and flow cytometry, with specificity confirmed in 19 publications .

  • Functional Role: Catalyzes the synthesis of arachidonic acid (AA) and eicosapentaenoate (EPA) from dietary precursors .

FAT1 Antibody (mAb198.3) in Cancer Therapy

• Mode of Action:

  • Binds FAT1 at the plasma membrane, inducing antibody internalization and inhibiting cancer cell migration .

  • Does not significantly affect apoptosis, suggesting a role in metastasis suppression rather than direct cytotoxicity .

• Preclinical Data:

  Model	Outcome
  In vitro CRC invasion	60% reduction in cell invasiveness post-treatment .
  Xenograft models	45% tumor growth inhibition compared to controls .

FADS1 Antibody in Metabolic Research

• Applications:

  • Detects FADS1 in insulin-secreting cells (INS-1E, Min6) and pancreatic islets, though commercial antibodies show variable specificity .

  • Validated for western blotting (WB) and immunoprecipitation (IP) with no cross-reactivity to FADS2 .

Technical Challenges in Antibody Validation

• FFAR1 Antibody Case Study:

  • Despite mRNA confirmation of FFAR1 expression in pancreatic β-cells, commercial antibodies failed to detect the protein reliably, highlighting the need for rigorous validation .

  • Recommendations:

    • Use siRNA knockdown or GFP-tagged proteins as orthogonal validation methods.

    • Prioritize antibodies with peer-reviewed validation data (e.g., FAT1 mAb198.3 , FADS1 ab126706 ).

Antibody Engineering Innovations

• Fc Optimization:

  • Mutations such as Met428Leu/Asn434Ser (LS mutations) enhance antibody half-life by improving FcRn binding .

  • Impact: 3–4-fold increase in serum persistence demonstrated in primate models .

• Species Cross-Reactivity:

  • FAT1 mAb198.3 cross-reacts with bovine spermatozoa, enabling translational studies in ruminants .

Critical Gaps and Future Directions

• FAE1-Specific Data: No peer-reviewed studies or commercial products referencing "FAE1 Antibody" were identified in the provided sources. This gap may indicate:

  • A nomenclature discrepancy (e.g., confusion with FAT1, FADS1, or FRA1).

  • A novel or less-characterized target requiring further investigation.

• Recommendations:

  • Validate query terminology with genomic databases (e.g., UniProt, HUGO Gene Nomenclature Committee).

  • Explore antibodies against homologous proteins (e.g., FAT1 for cancer, FADS1 for metabolic studies).